

Special Issue

Epigenomic and Genomic Studies of Cancers

Message from the Guest Editor

Genomic alterations are fundamental drivers of the hallmarks of cancer and represent critical targets for precision treatment. Multiple mutation-specific targeted therapies have received FDA approval for clinical cancer treatment, including inhibitors targeting KRAS G12C and EGFR T790M/L858R mutations, highlighting the therapeutic value of genomic profiling. Beyond genetic alterations, epigenetic regulation has emerged as a central layer controlling gene expression and cellular identity in cancer. Advances in 3D epigenomics have further expanded this field by revealing how higher-order chromatin architecture regulates enhancer-promoter interactions and transcriptional programs. Rapid advances in next-generation sequencing, single-cell multi-omics, and spatial genomics technologies continue to accelerate discoveries in cancer genomics and epigenomics, enabling systematic interrogation of tumor heterogeneity, clonal evolution, and tumor-microenvironment interactions.

Guest Editor

Dr. Yuxiang Wang

Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA

Deadline for manuscript submissions

20 August 2026

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/272181

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))